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The aim of this study was to determine the ergogenic effects and the safety
profile of a one-component higenamine supplement in female recreational athletes.
Twelve recreational female basketball players (age 29–41 years, oxygen consumption
(VO2max) > 30 ml·kg−1·min−1, with training > 5 h wk−1) were randomized either to
the higenamine group, or to the placebo group for 3 weeks. In order to determine
ergogenic effects and safety profile of higenamine administration, we assessed the
following variables before and after 3 weeks of supplementation: anthropometric
parameters, resting metabolic rate (RMR), exercise testing variables, serum free fatty
acids (FFAs), blood pressure, enzyme activity, urea, lipid profile, and complete blood
count. There were no differences between groups in anthropometric parameters,
including basal metabolic rate (BMR), RMR and body fat [p = 0.706 (Cohen’s d
0.223), p = 0.169 (Cohen’s d 0.857), and p = 0.223 (Cohen’s d 0.750), respectively],
FFAs [0.43 ± 0.03 vs. 0.54 ± 0.23, p = 0.206 (Cohen’s d 0.540)], neither significant
differences in cardiopulmonary parameters after the intervention period. Furthermore,
all measured outcome variables in the safety assessment were not significant, with
values remaining stable during the intervention period for participants in both groups.
This is the first study to document the effects and the safety profile of higenamine-
based dietary supplements at a specified dose in female recreational athletes. Our
data indicate that 21-day of supplementation with 75 mg higenamine would not result
in improving cardiopulmonary exercise fitness and weight loss in female recreational
athletes. Moreover, supplementation with 75 mg higenamine is safe and well-tolerated
in younger recreational female athletes.
Keywords: recreational athletes, female, ergogenic effects, safety assessment, higenamine, supplementation,
dietary supplement
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INTRODUCTION
Higenamine could be found as an ingredient of fat-burn and pre-
workout dietary supplements, which have become increasingly
popular among competitive and recreational athletes due to
its alleged ergogenic benefits (Cohen et al., 2019; Jagim et al.,
2019; Yen et al., 2020). Higenamine, an alkaloid (6,7,12-
trihydroxy-benzyl-1,2,3,4 tetrahydroisoquinoline), is found in
many different plant species. In dietary supplements and over-
the-counter products, it could be labeled in different names, such
as norcoclaurine, demethylcoclaurine, or the name of the plant
that is the source of higenamine: Aconitum japonicum, Nandina
domestica, Gnetum parvifolium, Asarum heterotropoides, etc.
(Okano et al., 2017; Grucza et al., 2018). As a non-selective
beta-agonist, higenamine could show chronotropic and inotropic
activity, has bronchodilatative effects, and enhances lipolysis
(Stajic et al., 2017). As a β2-agonist, higenamine was added
to the World Anti-doping Agency (WADA) prohibited list
in 2017 under the S3 category, which mainly includes drugs
for asthma treatment (WADA, 2017a; Yan et al., 2019; Feng
et al., 2020). Higenamine was prohibited at all times, in and
out-of-competition, which led to the fact that intentional and
unintentional use of higenamine can pose a risk to athletes’
sporting careers (Grucza et al., 2018). Substances may be included
in WADA prohibited list if they satisfy any two of the following
three criteria; (1) it has the potential to enhance or enhances sport
performance; (2) it represents an actual or potential health risk to
the athlete; and (3) it violates the spirit of sport (Agency Wa-D.,
2015). According to WADA’s report, positive cases of higenamine
misuse have been increasing yearly. Moreover, higenamine came
in second place among beta-2 agonists causing adverse analytical
finding (WADA, 2017b). However, there is no strong evidence
that higenamine has an ergogenic activity or an influence on
bronchodilation. The previously conducted study did not fully
address the underlying mechanisms of higenamine and therefore
the efficacy and safety of oral higenamine is not full understood
(Zhang et al., 2017). This is why anti-doping experts have raised
concerns about fulfillment of the criteria for inclusion in the
Prohibited List by higenamine (Stajic et al., 2017). Namely,
according to Heuberger et al., only five out of 23 substance
classes on the WADA prohibited list have robust evidence of
actually having the ability to enhance sports performance in
athletes (Heuberger and Cohen, 2019). Additionally there is still
a lack of studies that would appropriately address the safety of
the long-term use of higenamine-containing dietary supplements
among recreational athletes, especially females. According to
the previously observed findings the majority of users of fat-
burn supplements were women between the ages of 18 and
34 who are more likely than males to experience the side
effects of using this category of supplements (Jagim et al., 2019;
Jędrejko et al., 2021).
Therefore, the aim of the study was to determine the
ergogenic effects of a one-component higenamine supplement
in recreational female basketball players during the 21-day
administration period. Also, the study was conducted to examine
for the first time the safety profile of chronic higenamine intake
in female recreational athletes.
MATERIALS AND METHODS
Experimental Approach to the Problem
In order to investigate the effects of long term higenamine
supplementation, we assessed several variables prior and
after the study: anthropometric parameters (fat and muscle
content), resting metabolic rate (RMR), exercise testing variables
[oxygen consumption (VO2max) and ventilation] and metabolic
parameters [serum free fatty acid (FFA) oxidation]. In order
to determine the safety profile of higenamine, blood pressure,
enzyme activity, urea, creatinine, lipid profile, and complete
blood count were analyzed. The supplementation lasted for
21 days, during which female basketball players were on the
regular regimen of training. The experimental group received the
higenamine capsules (25 mg) three times per day for 21 days
following the instruction given by the manufacturer. Both groups
had oral intake and were on the same dosing regimen of triple
daily intake of active substance and placebo. The higenamine
capsules purchased at a local pharmacy. The higenamine
capsules were produced by Singular Sport (Higenamine by
Singular Sport, United States) and quality and quantity control
analysis was performed by local pharmaceutical company Essensa
(Essensa, Belgrade, Serbia). The Essensa company produced
the placebo capsules for study purposes that contained 100%
erythritol. The higenamine capsules contained microcrystalline
cellulose as excipient and both capsules were composed of
hydroxypropylmethylcellulose (HPMC). In order to ensure high
protocol adherence and promote participants’ commitment short
message service (SMS) reminder system was established as well
as communication via Viber group. At the final testing after
the intervention, the participants were asked to return the
remaining capsules.
The researchers counted the remaining capsules; the
compliance in both groups was 90%. Both groups and the
researchers were unaware of which group was receiving the
higenamine until the statistical analyses were finished.
Participants
The study included a randomized, double-blind, placebo-
controlled group design. The recreational female basketball
players were randomly allocated to the higenamine (n = 7)
or the placebo group (n = 7). At the beginning of the study,
two participants (one assigned to the placebo and the other to
the experimental group) decided to cease participation due to
personal reasons so the study involved 12 recreational female
basketball players. Before participation, athletes completed
medical history and physical activity questionnaires. Criteria for
inclusion in the study: VO2max > 30 ml·kg−1·min−1, with
training > 5 h·wk−1. Exclusion criteria for diseases that could
affect metabolism, such as: chronic diseases (neurological, renal,
immune, etc.), cardiovascular diseases (high blood pressure, heart
failure, cardiomyopathy, carditis, rheumatic heart disease, etc.),
metabolic disorder (diabetes, malabsorption, cachexia, and acid–
base imbalance), thyroid gland disease (hypothyroidism and
hyperthyroidism), respiratory diseases (asthma), recent surgery,
and acute infections.
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To ensure compliance, athletes were asked to take the capsules
before meals, the first one at 8 am, then at 1 pm and the
last one at 6 pm. Furthermore, athletes were required to
refrain from taking supplements and other medications and to
hold steady training and regular diet regimen. A total of 12
recreational female basketball players completed the study. The
physical and anthropometric characteristics of the athletes were
similar (Table 1).
All the experimental procedures in the current study followed
the guidelines laid down in the Declaration of Helsinki. The
Ethics Committee of the Sports Medicine Association of Serbia
approved the study. Before enrolling in the study, all participants
went through verbal and written consent processes.
Dietary Intake and Physical Activity
Participants were instructed to maintain their habitual dietary
intake throughout the study period. Dietary intake evaluation
was based on participants’ subjective retrospective report,
using the repeated 24-h recalls (24-h period prior to each
test day) as the assessment method. Participants reported
complete consumption of food and beverages conducted
by a trained nutritionist in accordance with predefined,
standardized protocol.
Participants were also instructed to maintain their usual
physical activity patterns during the entire course of the study.
Besides, they were required to report their training loads weekly,
filling in the standard short form of International Physical
Activity Questionnaire (IPAQ)1.
Anthropometric Characteristics
Anthropometric characteristics were measured before and after
the study. Body weight, body fat, basal metabolic rate (BMR),
and body mass index (BMI) were determined using the
bioimpedance method by body composition analyzer BC-418MA
(Tanita, Tokyo, Japan).
Resting metabolic rate was measured by indirect calorimetry
using desktop metabolic monitor Fitmate PRO (Fitmate,
COSMED, Italy) based on the oxygen consumption (VO2)
during rest.
Blood Samples Collection and Analysis
Blood samples (3 mL per whole blood BD Vacutainer R© spray-
coated K2EDTA tube and 10 ml per serum BD Vacutainer R©
SSTTM II Advance tube) were taken out of the antecubital
vein. Samples were collected twice: before and after the
study, in the morning hours (between 7:00 am and 9:00
am), following 12 h overnight fasting in the absence of prior
vigorous physical activity. Following collection, samples were
processed, and fresh samples were analyzed for complete blood
count on a fully automated hematology analyzer (Sysmex XT-
1800i, Sysmex, Japan) that used fluorescence flow cytometry
(FFC) technology: erythrocytes (RBC), hemoglobin (Hgb),
hematocrit (Hct), platelets (PLT), leukocytes (WBC), and
leukocyte formula. Blood samples were allowed to clot for 30 min
at room temperature. Serum was separated using centrifugation
1http://www.ipaq.ki.se/downloads.htm
2,000 × g, 10 min by table top centrifuge (LACE32, COLO
lab experts, Slovenia). One portion of serum was analyzed
immediately; biochemical analysis, glucose, urea, creatinine,
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), γ-glutamyl transferase (GGT), creatine kinase (CK), and
lipids parameters were analyzed on the biochemical module
Roche c501,which is an integral part of the integrated analyzer
(Cobas R© 6000 Roche Diagnostics, Germany) by the method
of spectrophotometric. One portion of the serum (3 mL)
was frozen at −80◦C until FFAs were analyzed. The FFAs
were determined by the extraction of total lipids according
to the method Folco using an internal standard 19–0. The
separation of lipid classes in the amino propylene column
(Agilent Technologies, United States), methylation, and were
analyzed fatty acid methyl esters by gas chromatography
(Shimadzu 2014, Japan).
Cardiopulmonary Exercise Testing and
Echocardiography Examination
Cardiopulmonary and echocardiography parameters were
determined before higenamine supplementation and after
21 days of supplementation. Cardiopulmonary exercise testing
(CPX) was performed on a treadmill (T-140, Cosmos, Germany),
twice (before and after the study), according to maximal
protocol. The exercise intensity was progressively increased,
while oxygen and CO2 concentration of the inhaled and
exhaled air were measured. A test was considered maximal
if participants achieved 90% or more of predicted maximal
heart rate (HR max) for age and sex, a plateau in VO2 was
reached despite increased workload, a respiratory exchange
ratio (RER) was greater than 1.00, and subjects reached
volitional exhaustion. The maximal HR max was calculated
as 220 minus the athlete age. Expiratory gases were collected
on a breath-by-breath basis, and analyzed by metabolic cart
(Quarck b2, COSMED, Italy). Ventilatory anaerobic threshold
(VAT) was determined by the “V-slope” analysis of VO2 vs.
carbon dioxide production (VCO2). The values of VO2 at
Ventilatory Threshold [VT (VT I and VT II)] and at peak
exercise (VO2 max) are expressed as ml O2kg−1min−1 during
the 30 s in which the examined event occurred and printed
using rolling averages every 10 s. The predicted peak of
VO2 was defined according to current recommendations.
The predicted peak O2 pulse was calculated as the predicted
peak of VO2· (predicted maximal HR) −1. The RER 1.2 was
considered as a satisfactory effort for athletes. Hemodynamic
parameters obtained during the test were peak systolic blood
pressure [SBP max (mmHg)], peak diastolic blood pressure
[DBP max (mmHg)], HR max, as well as maximum voluntary
ventilation (MVV), oxygen pulse. Criteria for test termination
was determined by (a) VO2 plateau, (b) RER ≥ 1.2, (c)
rating of perceived exertion ≥ 9/10, or maximal volitional
exhaustion, and (d) HR above 90% of theoretical HR max (220
minus athlete age).
Standard 2D echocardiography was performed prior and
after the study (Logiq 5, General Electric, United States).
Athletes self-monitored blood pressure using device Blood
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Before After Before After
Age (years) 32.83 ± 5.15 / / 33.00 ± 2.45 / / / /
Height (m) 1.78 ± 0.09 / / 1.77 ± 0.08 / / / /
Weight (kg) 69.75 ± 11.46 69.87 ± 11.59 0.725 70.72 ± 5.50 71.08 ± 4.95 0.565 0.856 0.818
0.162 0.248 0.108 0.136
BMI (kgm−2) 22.03 ± 2.08 21.98 ± 1.90 0.776 22.67 ± 1.87 22.73 ± 2.02 0.737 0.591 0.523
0.122 0.131 0.324 0.382
BMR (kcal per day) 1486.17 ± 168.07 1491.17 ± 153.54 0.638 1488.67 ± 120.47 1463.00 ± 90.07 0.217 0.977 0.706*
0.200 0.576 0.017 0.224
Body fat (%) 28.28 ± 5.45 28.25 ± 6.21 0.942 29.95 ± 5.06 32.05 ± 3.58 0.072 0.595 0.223*
0.028 0.931 0.318 0.750
RMR (kcal per day) 1346.33 ± 289.04 1413.33 ± 251.59 0.518 1211.83 ± 413.96 1169.83 ± 313.48 0.683 0.529 0.169*
0.284 0.177 0.377 0.857
Results are expressed as mean ± standard deviations. Significance: p < 0.05 was obtained by paired t-test.
BMI, body mass index; BMR, basal metabolic rate; RMR, resting metabolic rate.
*No significant difference in anthropometric parameters within study groups, including BMR (p = 0.706), RMR (p = 0.169), and body fat (p = 0.223).
Pressure Monitor (BP B1, Microlife, Microlife AG, Switzerland)
every morning.
Recording of Adverse Events
The adverse events were assessed by telephone interviews with
participants each day during the 21-day intervention period, and
they were recorded on the adverse event form throughout the
study. The participants were asked to self-report any health-
related problems or symptoms they were experiencing during the
intervention period.
Statistical Analysis
Numerical data were presented by arithmetic mean and standard
deviation. Normal distribution was evaluated using mathematical
(coefficient of variation, skewness, kurtosis, Kolmogorov–
Smirnov test, and Shapiro-Wilk test) and graphical methods
(histogram, Q–Q diagram, and a box plot). Interventional
and control groups were compared with Student t-test, and
values before and after in each group by t-test for dependent
samples. As a measure of effect size, Cohen’s d was used for
paired or independent t-tests where appropriate. For exploring
associations between parameters, we used the Pearson linear
correlation coefficient. The results were expressed as mean value
and standard deviation. All statistical methods were considered
significant for the level of 0.05. The analysis was realized in
software IBM SPSS version 21 (IBM Corp. Released 2012. IBM
SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM
Corp.). As the conclusion according to the test statistic will be
the same as according to the previously reported p-value for the
chosen error of the first type α = 0.05, we will report p-value
with the effect size expressed by Cohen’s d for student t-test for
two independent as well as for paired samples where appropriate.
Those values are reported in all the tables. G power software ver.
3.1.9.2 was used to perform power analysis calculations.
RESULTS
A total of 12 female recreational basketball players with mean
age of 33.00 ± 2.45 years were recruited. They were compared
within two groups: Higenamine (Experimental) and Placebo
before and after the intervention period of 21 days, as well as
between the groups.
Anthropometric Parameters
There was no significant change in anthropometric parameters
within the study groups, including BMR, RMR and body fat
[p = 0.706 (Cohen’s d 0.223), p = 0.169 (Cohen’s d 0.857),
p= 0.223 (Cohen’s d 0.750), respectively] (Table 1).
Biochemical and Metabolic Parameters
According to blood parameters, there was a significant change
in MCV and MCHC in placebo group before and after the
intervention period (p = 0.048 and 0.049, respectively). There
were no differences in any blood count parameters between
the groups before and after the intervention period (Table 2).
Moreover, the athletes did not differ in any of the analyzed
metabolic parameters, except blood glucose concentration
in the placebo group before and after the study finished
(p= 0.035) (Table 3).
Dietary Intake and Physical Activity
According to the IPAQ participant’s average calorie consumption
in average per week was between 1,820 and 2,650 kcal·week−1,
which classified them in the group of high physical activity level.
Participants maintained their usual physical activity patterns
during the entire course of the study as it was requested from
the participants. Food consumption analyses, measured by 24-h
recall repeated on random days, confirmed stable dietary intake
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TABLE 2 | Blood parameters in placebo and higenamine groups before and after the treatment.










WBC (109 L−1) 5.89 ± 1.27 6.97 ± 1.09 0.094 6.90 ± 2.14 6.46 ± 2.42 0.338 0.345 0.649
0.847 0.403 0.574 0.272
RBC (1012 L−1) 4.33 ± 0.55 4.40 ± 0.48 0.344 4.48 ± 0.18 4.53 ± 0.28 0.651 0.552 0.556
0.458 0.181 0.367 0.331
Hgb (gL−1) 124.50 ± 11.26 127.17 ± 7.91 0.175 129.50 ± 5.92 131.83 ± 8.08 0.446 0.358 0.336
0.646 0.337 0.556 0.583
Hct (LL−1) 0.38 ± 0.04 0.38 ± 0.03 0.453 0.39 ± 0.02 0.39 ± 0.02 0.541 0.473 0.390
0.000 0.000 0.316 0.333
MCV (fL) 87.05 ± 5.60 86.78 ± 5.50 0.131 86.52 ± 0.86 86.77 ± 1.56 0.498 0.826 0.994
0.740 0.298 0.132 0.002
MCH (pg) 28.97 ± 2.86 29.15 ± 2.96 0.048* 28.90 ± 0.35 29.08 ± 0.30 0.325 0.957 0.957
1.097 0.438 0.034 0.033
MCHC (gL−1) 332.50 ± 17.76 335.33 ± 19.46 0.047* 334.17 ± 4.45 335.33 ± 4.68 0.528 0.828 1.000
1.067 0.275 0.12 0.000
PLT (109 L−1) 225.83 ± 19.55 234.17 ± 18.27 0.152 253.50 ± 64.38 251.00 ± 63.74 0.828 0.338 0.548
0.690 0.094 0.582 0.359
Neutrophils (%) 50.93 ± 8.89 57.47 ± 10.63 0.145 51.55 ± 7.96 41.35 ± 4.48 0.928 0.902 0.223
0.705 1.978 0.073 1.976
Lymphocytes (%) 37.32 ± 9.28 31.80 ± 10.91 0.148 37.83 ± 7.46 37.10 ± 3.60 0.756 0.917 0.285
0.699 0.134 0.061 0.652
Monocytes (%) 8.65 ± 1.49 8.20 ± 0.87 0.297 7.35 ± 1.71 7.75 ± 1.82 0.453 0.190 0.597
0.474 0.332 0.811 0.315
Eosinophils (%) 2.45 ± 0.57 1.95 ± 0.65 0.070 2.63 ± 1.98 3.10 ± 2.31 0.060 0.831 0.286
0.934 1.005 0.124 0.678
Basophils (%) 0.65 ± 0.36 0.58 ± 0.23 0.675 0.63 ± 0.19 0.70 ± 0.11 0.328 0.922 0.291
0.192 0.455 0.069 0.666
Neutrophils (109 L−1) 3.02 ± 0.85 4.01 ± 0.99 0.095 3.49 ± 0.84 3.29 ± 1.13 0.588 0.358 0.268
0.841 0.238 0.556 0.678
Lymphocytes (109 L−1) 2.19 ± 0.73 2.21 ± 0.86 0.861 2.66 ± 1.15 2.39 ± 0.89 0.142 0.424 0.735
0.069 0.718 0.488 0.206
Monocytes (109 L−1) 0.50 ± 0.11 0.57 ± 0.11 0.099 0.51 ± 0.20 0.51 ± 0.24 0.920 0.943 0.548
0.855 0.000 0.062 0.321
Eosinophils (109 L−1) 0.14 ± 0.05 0.13 ± 0.04 0.723 0.20 ± 0.22 0.23 ± 0.27 0.276 0.500 0.399
0.285 0.520 0.376 0.518
Basophils (109 L−1) 0.04 ± 0.02 0.04 ± 0.02 0.415 0.05 ± 0.02 0.05 ± 0.02 1.000 0.501 0.755
0.000 0.000 0.500 0.500
Results are expressed as mean ± standard deviations. Significance was considered for p < 0.05.
WBC, white blood cell; RBC, red blood cell; MCV, mean cell volume; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin concentration.
*There was a significant difference in MCV and MCHC in placebo group before and after the intervention period (p = 0.048 and 0.049). There were no significant
differences in any blood count parameters between the groups before and after the intervention period.
during the experimental period, since no significant differences
were observed in energy intake.
Free Fatty Acid
Results of FFAs are presented in Table 3. FFAs did not change
significantly during the intervention period in the placebo group
[0.43 ± 0.03 vs. 0.54 ± 0.23, p = 0.206 (Cohen’s d 0.540)],
neither in the higenamine group [0.48 ± 0.16 vs. 0.53 ± 0.25,
p = 0.537 (Cohen’s d 0.278)]. There was no difference in FFAs
values between the placebo and the higenamine group before the
intervention, neither after the study finished [p= 0.475 (Cohen’s
d 0.434), p= 0.896 (Cohen’s d 0.042), respectively].
Cardiopulmonary and Echocardiography
Parameters
The only significant difference noticed after the 21-day
intervention period was the slightly lower value of RER within
the higenamine group after the supplementation [1.08 ± 0.07
vs. 1.05 ± 0.07, p = 0.020 (Cohen’s d 1.154)]. Still, there
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Placebo n = 6 p Cohen’s
d






Before After Before After
Glucose (mmol·L−1) 4.52 ± 0.32 4.98 ± 0.41 0.035* 4.45 ± 0.42 4.73 ± 0.24 0.108 0.764 0.229
1.158 0.798 0.187 0.744
Urea (mmol·L−1) 4.65 ± 0.80 4.32 ± 0.82 0.472 3.87 ± 0.87 3.90 ± 0.81 0.921 0.135 0.396
0.314 0.038 0.933 0.515
Creatinine (µmol·L−1) 83.67 ± 11.36 78.50 ± 10.60 0.141 76.33 ± 9.56 75.00 ± 10.84 0.444 0.254 0.584
0.713 0.338 0.699 0.326
AST (IU·L−1) 15.83 ± 2.64 16.17 ± 3.37 0.611 16.67 ± 4.97 15.50 ± 1.97 0.420 0.724 0.685
0.226 0.359 0.211 0.243
ALT (IU·L−1) 11.67 ± 3.01 12.17 ± 2.86 0.296 11.17 ± 3.82 12.00 ± 3.29 0.289 0.806 0.927
0.475 0.482 0.145 0.055
GGT (IU·L−1) 10.50 ± 2.51 10.83 ± 2.71 0.465 14.00 ± 3.16 14.33 ± 3.08 0.465 0.060 0.063
0.320 0.321 1.227 1.207
CK (IU·L−1) 89.00 ± 41.02 106.17 ± 58.10 0.139 126.00 ± 140.29 106.17 ± 58.69 0.601 0.549 1.000
0.717 0.228 0.358 0.000
Cholesterol (mmol·L−1) 3.91 ± 0.82 3.93 ± 0.72 0.863 4.26 ± 0.64 4.30 ± 0.74 0.827 0.431 0.406
0.075 0.107 0.476 0.507
HDL-C (mmol·L−1) 1.58 ± 0.19 1.59 ± 0.22 0.894 1.35 ± 0.33 1.37 ± 0.29 0.548 0.169 0.163
0.057 0.293 0.854 0.855
LDL-C (mmol·L−1) 2.04 ± 0.65 2.01 ± 0.55 0.697 2.50 ± 0.76 2.57 ± 0.77 0.624 0.282 0.172
0.165 0.209 0.651 0.837
Triglycerides (mmol·L−1) 0.66 ± 0.07 0.74 ± 0.19 0.327 0.91 ± 0.33 0.80 ± 0.27 0.303 0.112 0.691
0.412 0.433 1.048 0.257
FFA (mmol·L−1) 0.43 ± 0.03 0.54 ± 0.23 0.206 0.48 ± 0.16 0.53 ± 0.25 0.537 0.475† 0.896†
0.540 0.278 0.434 0.042
Results are expressed as mean ± standard deviations. Significance was considered for p < 0.05.
GGT, γ-glutamyl transferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine kinase; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol. FFA, free fatty acids.
*There was a significant difference in blood glucose concentration in the placebo group before and after the study finished (p = 0.035). There were no significant
differences in any metabolic parameters between the groups before and after the intervention period.
†There was no significant difference in free fatty acids (FFA) values between in the placebo and the higenamine group before the intervention (p = 0.475), neither after the
study finished (p = 0.896).
was no significant difference between the placebo and the
higenamine group (1.05 ± 0.06 vs. 1.05 ± 0.07, p = 0.931).
There were no significant differences in cardiopulmonary
parameters: maximum oxygen consumption (VO2 max),
maximum ventilation (VE max), HR max, recovery of HR in
the first, second, or third minute, as well as ejection fraction
(EF), mitral inflow (E/A) on echocardiography. All measured
cardiopulmonary and echocardiography parameters are
presented in Table 4.
During the 21-day intervention, there were no statistically
significant changes of systolic or DBP between the higenamine
and the placebo groups, neither within groups.
Adverse Effects
Adverse events were self-reported by the participants regardless
of suspected causal relationship to the study treatments. Athletes
from both groups, the placebo, and the higenamine group,
reported adverse events. A total of 23 side effects were reported
during the intervention period from participants in both groups.
Two of the six athletes from the placebo group experienced a
headache at the beginning of the study. In the higenamine group
four of the six athletes also self-reported adverse events such as
headache and one reported dry mouth besides headache: the first
participant experienced headache on the 1st and 7th day of the
intervention; the second participant experienced headache on the
2nd, 3rd, and 4th day; the third participant reported headache
on the 9th and 13th day and the fourth participant reported
dry mouth on the 2nd and 3rd day. All the reported adverse
events were transient. No other adverse events were noted for
any participants.
DISCUSSION
Findings from this study indicate that 21-day supplementation
with higenamine does not result in a statistically significant
change in any of the measured outcome variables. These
data are specific to a sample of healthy, young female
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Placebo n = 6 p Cohen’s
d






Before After Before After
Echocardiography parameters
EF (%) 67.50 ± 4.76 67.67 ± 3.88 0.908 69.00 ± 2.53 70.00 ± 0.00 0.377 0.511 0.201
0.050 0.395 0.394 0.849
E (VP m· s−1) 0.93 ± 0.18 0.92 ± 0.15 0.919 0.99 ± 0.15 0.93 ± 0.10 0.318 0.501 0.912
0.259 0.463 0.362 0.078
A (VP m· s−1) 0.75 ± 0.18 0.73 ± 0.17 0.636 0.67 ± 0.06 0.64 ± 0.13 0.505 0.369 0.336
0.276 0.276 0.596 0.595
Cardiopulmonary parameters
VO2 max (ml·kg−1·min−1) 37.32 ± 7.66 39.58 ± 7.00 0.285 38.20 ± 6.39 36.92 ± 4.36 0.296 0.833 0.447
0.488 0.474 0.125 0.456
VO2 max (ml·min−1) 2587.17 ± 626.27 2763.82 ± 603.49 0.223 2707.40 ± 557.99 2624.38 ± 371.27 0.399 0.733 0.640
0.569 0.377 0.203 0.278
VE max (L·min−1) 84.33 ± 22.90 87.78 ± 21.40 0.493 88.35 ± 16.94 83.57 ± 18.07 0.249 0.737 0.720
0.302 0.534 0.200 0.213
SBP max (mmHg) 158.33 ± 26.39 158.33 ± 14.72 1.000 160.00 ± 8.94 165.00 ± 12.25 0.203 0.886 0.414
0.000 0.597 0.085 0.493
DBP max (mmHg) 66.67 ± 8.16 65.00 ± 8.37 0.363 61.67 ± 4.08 61.67 ± 4.08 1.000 0.209 0.401
0.409 0.000 0.775 0.506
HR on VT II (bpm·min−1) 166.00 ± 7.35 168.83 ± 11.48 0.480 164.67 ± 6.92 158.00 ± 17.26 0.231 0.753 0.229
0.311 0.557 0.186 0.739
HR on VT II (%) 92.05 ± 4.16 93.13 ± 3.09 0.662 93.77 ± 4.15 90.25 ± 11.11 0.297 0.491 0.554
0.189 0.475 0.414 0.353
HR on VT I (bpm·min−1) 148.33 ± 24.09 149.67 ± 16.88 0.702 142.50 ± 8.83 148.50 ± 4.97 0.204 0.590 0.874
0.166 0.596 0.321 0.094
HR on VT I (%) 81.72 ± 8.47 82.45 ± 6.04 0.601 81.20 ± 5.61 84.67 ± 2.41 0.144 0.903 0.423
0.227 0.707 0.072 0.483
HR max (bpm·min−1) 180.67 ± 10.63 181.17 ± 8.33 0.765 175.67 ± 5.82 175.50 ± 7.31 0.889 0.336 0.239
0.129 0.061 0.583 0.724
HR max (%) 94.58 ± 8.31 94.85 ± 7.66 0.768 93.90 ± 3.84 93.80 ± 4.36 0.876 0.859 0.776
0.129 0.067 0.105 0.168
HR rest 1 min (bpm·min−1) 153.17 ± 13.20 151.50 ± 8.94 0.575 149.67 ± 6.19 146.67 ± 9.67 0.256 0.569 0.390
0.246 0.524 0.340 0.519
HR rest 2 min (bpm·min−1) 130.67 ± 13.72 126.67 ± 11.99 0.430 129.67 ± 7.99 125.17 ± 12.77 0.178 0.880 0.838
0.285 0.562 0.089 0.121
HR rest 3 min (bpm·min−1) 118.00 ± 13.55 117.00 ± 10.00 0.835 117.17 ± 12.12 112.67 ± 13.59 0.093 0.913 0.543
0.090 0.848 0.065 0.363
MVV (L·min−1) 151.67 ± 17.29 151.67 ± 17.29 1.000 151.58 ± 15.13 151.57 ± 15.12 0.363 0.993 0.992
0.000 0.001 0.006 0.006
O2 (HR) −1 (ml·bpm−1) 14.33 ± 3.50 15.08 ± 3.23 0.287 15.75 ± 3.40 14.33 ± 1.97 0.129 0.494 0.638
0.238 0.525 0.412 0.280
VE/VCO2 slope 28.65 ± 3.56 30.23 ± 2.68 0.256 27.10 ± 5.78 27.83 ± 2.27 0.721 0.588 0.125
0.523 0.147 0.323 0.966
RER 1.06 ± 0.07 1.05 ± 0.06 0.537 1.08 ± 0.07 1.05 ± 0.07 0.020* 0.597 0.931*
0.236 1.154 0.286 0.000
Test duration (min) 8.52 ± 2.99 9.17 ± 2.30 0.204 7.87 ± 2.64 9.35 ± 3.18 0.063 0.698 0.915
0.592 0.971 0.230 0.065
Results are expressed as mean ± standard deviations. Significance was considered for p < 0.05.
EF, ejection fraction; E/A, mitral inflow; VO2 max, maximum oxygen consumption; VE max, maximum ventilation; SBP max, maximum systolic blood pressure; DBP max,
maximum diastolic blood pressure; HR max, maximum heart rate; VT I, first ventilatory threshold; VT II, second ventilatory threshold; MVV, maximum voluntary ventilation;
O2 (HR) −1, oxygen pulse; RER, respiratory exchange ratio; bpm (beat per minute).
*A significant difference noticed after the 21-day intervention period was the slightly lower value of RER within higenamine group after the supplementation (p = 0.020).
There was no significant difference between the placebo and the higenamine group (p= 0.931). There were no significant differences in cardiopulmonary parameters: VO2
max, maximum ventilation (VE max), HR max, recovery of HR in the first, second, or third minute, as well as ejection fraction (EF), mitral inflow (E/A) on echocardiography.
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recreational athletes consuming daily 75 mg of higenamine
with respect to the chosen outcomes measures only. According
to our data, supplementation with 75 mg higenamine is
safe and well-tolerated in younger recreational female athletes
(Jagim et al., 2019).
The characteristics of the athletes enrolled in the study were
very similar, and there were no differences between the groups
(Table 1). Participants were taking 75 mg of higenamine daily
divided into three doses, following the instructions for use given
by the supplement manufacturer. According to the previously
observed findings, this dose of higenamine is a standard dose
found in dietary supplements. Namely, Cohen et al. analyzed
dietary supplements available for sale in the United States for the
presence and quantity of higenamine and reported that average
dosages of 62 ± 6.0 mg per serving of higenamine were found
in dietary supplements. Moreover, the same researchers have
shown that the quantity of higenamine in supplements can vary
from 0.01 to 200% relative to the declared dose (Cohen et al.,
2019). Therefore, in this study, the declared amount of 75 mg,
which corresponds to the dose to which consumers are most
often exposed in dietary supplements, was analytically confirmed
before the beginning of the study.
After the 21-day intervention period, there were no differences
between and within the groups, in the measured value of
RMR, neither difference in bodyweight and total body fat
(%) (Table 1). Moreover, after the 21-days of treatment, there
was no increase in the mobilization of fatty acids, which was
assessed by measuring fasting concentrations of fatty acids
(Table 3). Data in the literature have shown that beta2-agonists
has the potential to enhance performance, lipolysis, and increase
thermogenesis (Riiser et al., 2020). Furthermore, as a non-
selective beta-agonist, higenamine could also have agonistic
activity on beta3-receptors mainly expressed in white adipose
tissue, which could also result in fat loss by stimulating fatty acid
mobilization and, directly or indirectly, fat oxidation (Hostrup
et al., 2020). However, a limited number of human studies
have examined lipolytic and thermogenic effects of higenamine.
The only published human study determining the impact of
a higenamine-based supplement on measures of lipolysis and
metabolic rate was the study conducted by Lee et al. (2013). In
this study, the authors examined the acute effect of a supplement
that contained besides higenamine, also Yohimbe bark extract
and caffeine, both stimulants. Acute oral administration of this
higenamine-based supplement led to an increase in energy
expenditure and circulating fatty acids, including an increase
in blood pressure and HR in the group of healthy, active,
and young male and female participants. Since each of these
three components could exert these effects according to their
mechanism of action, the authors were not able to conclude
whether higenamine influenced the measured outcomes. In
another study conducted by the same group of authors, in
which one group of the male recreational participants had
been taking higenamine during 8 weeks, only safety profile of
higenamine supplements was examined (Bloomer et al., 2015).
On the contrary, in our study the effects were monitored
both before the start of the study and after the end of the
study, at least 12 h after the ingestion of the last capsule
so we did not measure acute effects as it was performed
in the study conducted by Lee et al. (2013). Considering
that long-term increases in energy expenditure and lipolysis
would most likely lead to changes in body weight and body
composition it would be realistic to expect any significant change
in the higenamine group after 21 days of treatment. However,
no significant differences were found between the groups in
any measured parameters that could indicate an increase in
energy expenditure, weight loss, or fat oxidation, including lipid
status parameters.
As it is presented in Table 4, there were no differences in
almost any of the cardiopulmonary parameters between groups,
neither within the higenamine group, after the intervention
period. The only statistically significant change noticed after
the 21-days intervention period was the slightly lower value of
RER within higenamine group after the treatment although no
statistical significance was reached between the groups. The RER
[(CO2 production· (O2 uptake) −1] increase with the exercise
intensity and measured under steady-state is commonly used to
indirectly determine the relative contribution of carbohydrate
and lipids to overall expenditure, whereas high RER suggests
carbohydrate oxidation and low RER predominantly lipid
oxidation. The RER is affected by factors such as diet and
previous exercise, and a sedentary lifestyle increases the RER
shifting metabolism from lipid to predominantly carbohydrate
oxidation and fat deposition (Ramos-Jiménez et al., 2008).
Higenamine supplementation resulted in a subtle decrease in
RER in female participants. Still, this change did not result
in an increase in serum-FFAs, fat mass, or in any other
related parameter.
In vivo and in vitro studies showed that higenamine could
exert positive inotropic and chronotropic effects, as well as
bronchodilator effects, as a result of its beta2-agonistic activity
(Zhang et al., 2017). These effects were also demonstrated in
human studies, which included healthy volunteers or patients
with heart disease or suspected heart disease. However, in
all these studies reporting consistently increased HR and
variable effects on blood pressure followed by dyspnea,
dizziness, and other adverse effects, higenamine was administered
intravenously, mostly using gradual infusions in doses of 2.5
or 5 mg higenamine (Cohen et al., 2019). Furthermore, the
bronchodilator effects of higenamine were only demonstrated in
in vitro studies (Kato et al., 2017; Zhang et al., 2017), and the
safety profiles of higenamine are based on a small population of
patients (Zhang et al., 2017).
While the pharmacokinetics of higenamine after intravenous
administration has been intensively studied in animals and
humans, the data are scarce regarding the oral route of
administration in humans. The only data in the literature are
those obtained in the rabbit and rat model showing very poor
bioavailability of higenamine (Lo and Chen, 1996; Wang et al.,
2020). Moreover, there are no studies providing data that would
allow comparison of intravenous and oral doses of higenamine.
Therefore, it is still unknown what doses of higenamine taken
orally can lead to the effects on the cardiorespiratory system
observed after intravenous administration in vivo and in vitro
studies. However, the results of our study indicate that 75 mg
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of higenamine taken during 21 days would not cause any
cardiopulmonary effects.
After intravenous administration, higenamine has a very
short half-life, almost ninety-four percent of higenamine can be
eliminated from the body within 30 min (Feng et al., 2012).
This could lead to the conclusion that no physiological effect
can be detected 12 h after the last dose taken. However, the
group of authors who measured urine concentration after 7 days
of repeated Plumula nelumbinis capsule administration, showed
that even 3 days after drug withdrawal, higenamine could be
detected in urine at concentrations ≥ 10 ng/mL which is WADA
reporting limit (Yan et al., 2019). These data strongly indicate
differences in the pharmacokinetics of higenamine following
oral and intravenous administration and thus could explain the
difference in physiological effect in two routes of administration.
In order to assess the safety of chronic administration of
higenamine at a dose of 75 mg, complete blood counts, enzymes
(CK, AST, and ALT), urea, creatine, lipid parameters, and
blood pressure measures were taken into account. In the safety
assessment, cardiopulmonary parameters were also taken into
consideration, and adverse events were recorded during and
7 days after the intervention period.
All measured outcome variables in this study were not
significant, with values remaining stable during the intervention
period for participants in both groups (Tables 2, 3). No changes
in blood pressure were observed between the groups as well
as within the higenamine group. The only adverse events that
were reported by female recreational athletes were headache
occurred in participants from both (placebo and intervention)
groups, and dry mouth, which was reported only by one
participant in higenamine groups. Both of these adverse events
were self-reported in the first days of the intervention. Data
in the literature have shown that intravenous administration
of higenamine in healthy volunteers could be associated with
the occurrence of headache and dry mouth (Zhang et al.,
2017; Cohen et al., 2019). In our study such effects were
reported with oral administration of higenamine, although
headache was reported in the placebo group, in addition to
the higenamine group In the above mentioned study, in which
the safety of higenamine supplementation was monitored in
doses of approximately 100 mg for 8 weeks in male healthy
recreational participants, there are no reported changes in
measured cardiopulmonary parameters, neither any adverse
events (Bloomer et al., 2015). One case report of the adverse effect
of higenamine in young men who developed rhabdomyolysis
after consuming a higenamine-based supplement and completed
intensive exercise routine was published in the literature (Jeter
et al., 2015). However, the case report did not provide any
information on the amount of higenamine and other ingredients
present in the supplement.
Although the underlying mechanisms of higenamine have
not been fully understood and data. of both safety/unsafety
and ergogenic effects of orally administrated higenamine is
still lacking, higenamine was added to the WADA prohibited
list, and ever since 2017 higenamine-containing supplements
and products can pose an immediate risk to competitive
athletes’ careers.
The key limitation of the present study is a small sample
of recreational athletes that potentially decreased the chance of
finding significant differences in measured clinical outcomes.
However, as it is easy to see in the results, there are only
a few parameters with large effect size, but this difference is
not clinically important, so it allows us to conclude that all
insignificant p-values are representative for this experimental
situation. The sample size of 6 respondents per group was
enough for some outcomes, like body fat (%) and HR rest, but
insufficient for some other. That is why further investigations
with larger sample size groups are needed. According to the
chosen error of the first type, total number of respondents
of 12, and achieved effect size (Cohen’s d) of 0.931 for body
fat (%), and of 0.848 for HR after 3 min of rest, the study
power was 83.50 and 76.25%, respectively. Furthermore, in
order to extend our findings, additional study involving the
use of different dosages of higenamine is needed, However,
the advantage of the study is the vast array of parameters
that have been measured in order to address the efficacy
and safety of the long-term use of higenamine-containing
dietary supplements. In addition, this is the first study
to document the effects and safety profile of higenamine-
based dietary supplements at a specified dose in female
recreational athletes.
In conclusion, 21-day supplementation with 75 mg
higenamine does not result in changing of cardiopulmonary
exercise fitness nor in the effect of weight loss in female
recreational athletes. Moreover, our data indicate that
supplementation with 75 mg higenamine is safe and
well-tolerated in younger female recreational athletes.
CONCLUSION
The current study demonstrates the safety of oral use of
higenamine at 75 mg doses for 3 weeks in female recreational
athletes. Another important aspect of this study is that these
results indicate that daily intake of 75 mg higenamine during
3 weeks would not result in improving cardiopulmonary exercise
fitness or weight loss. All of the above leads to the conclusion
that higenamine under these conditions of application does not
exhibit beta-agonistic activity, which was the criteria for adding
higenamine on the WADA Prohibited List.
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